---
title: "Intellicheck | 10-Q: FY2026 Q1 Revenue Misses Estimate at USD 5.524 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286152865.md"
datetime: "2026-05-12T20:28:07.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286152865.md)
  - [en](https://longbridge.com/en/news/286152865.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286152865.md)
---

# Intellicheck | 10-Q: FY2026 Q1 Revenue Misses Estimate at USD 5.524 M

Revenue: As of FY2026 Q1, the actual value is USD 5.524 M, missing the estimate of USD 5.678 M.

EPS: As of FY2026 Q1, the actual value is USD 0.03.

EBIT: As of FY2026 Q1, the actual value is USD 448 K.

Intellicheck, Inc. operates as a single reportable segment .

#### Revenue

-   Total revenues for the three months ended March 31, 2026, increased by $630, or 13%, to $5,524, compared to $4,894 for the same period in 2025 .
-   SaaS revenue increased by $646, or 13%, to $5,514 for the three months ended March 31, 2026, from $4,868 in the prior year period .
-   Equipment revenue remained constant at $6 for both periods .
-   Other revenue decreased to $4 for the three months ended March 31, 2026, from $20 in the prior year period .

#### Profitability

-   Gross profit increased by $633, or 14%, to $5,025 for the three months ended March 31, 2026, from $4,392 for the same period in 2025 .
-   Gross profit as a percentage of revenues was 91% for the three months ended March 31, 2026, up from 90% in 2025 .
-   Operating expenses decreased by $257, or 5%, to $4,483 for the three months ended March 31, 2026, compared to $4,740 for the same period in 2025, primarily due to a lower headcount .
    -   Selling, general and administrative expenses were $3,242 for the three months ended March 31, 2026, compared to $3,453 for the same period in 2025 .
    -   Research and development expenses were $1,241 for the three months ended March 31, 2026, compared to $1,287 for the same period in 2025 .
-   Income from operations was $542 for the three months ended March 31, 2026, a significant improvement from a loss of - $348 for the same period in 2025 .
-   Net income was $636 for the three months ended March 31, 2026, compared to a net loss of - $318 for the three months ended March 31, 2025 .

#### Cash Flow and Liquidity

-   Net cash provided by operating activities was $445 for the three months ended March 31, 2026, down from $750 for the same period in 2025 .
-   Net cash used in investing activities was - $33 for the three months ended March 31, 2026, compared to - $173 for the same period in 2025 .
-   Net cash used in financing activities was $0 for the three months ended March 31, 2026, compared to - $95 for the same period in 2025 .
-   As of March 31, 2026, cash and cash equivalents totaled $10,062, an increase from $9,650 as of December 31, 2025 .
-   Working capital as of March 31, 2026, was $11,119 .
-   The accumulated deficit was - $132,574 as of March 31, 2026 .

#### Other Key Metrics

-   Deferred revenue was $2,922 as of March 31, 2026, up from $1,661 as of December 31, 2025 . Of the December 31, 2025 balance, $1,224 was recognized as revenue in the first three months of 2026 .
-   Accounts receivable, net, was $5,740 as of March 31, 2026, compared to $3,365 as of December 31, 2025 .
-   As of March 31, 2026, there was approximately $2,755 of total unrecognized compensation costs related to unvested stock options and RSUs, expected to be recognized over a weighted-average period of approximately 2.59 years .
-   The company had 1,412,316 shares available for future grants under its equity compensation plans as of March 31, 2026 .
-   Federal Net Operating Loss (NOL) carryforwards were approximately $30,520 as of December 31, 2025, with $10,892 expiring between 2035 and 2037, and the remaining $19,628 carried forward indefinitely subject to an 80% taxable income limitation .
-   State NOL carryforwards were approximately $3,670 as of December 31, 2025 .

#### Non-GAAP Measures

-   Adjusted Gross Profit was $5,162 (93.4% of revenues) for the three months ended March 31, 2026, compared to $4,495 (91.8% of revenues) for the same period in 2025 .
-   Adjusted EBITDA was $935 for the three months ended March 31, 2026, compared to - $17 for the same period in 2025 .

#### Future Outlook and Strategy

Intellicheck, Inc. anticipates that its available cash and expected cash from operations will be sufficient to meet working capital and capital expenditure requirements for at least the next 12 months from the report date . The company retains the option to raise additional funds for various business contingencies, though there is no assurance such funds can be secured on satisfactory terms .

### Related Stocks

- [IDN.US](https://longbridge.com/en/quote/IDN.US.md)

## Related News & Research

- [Intellicheck Q1 revenue misses analyst estimates](https://longbridge.com/en/news/286150397.md)
- [Intellicheck Stockholders Approve Directors, Auditor and Compensation](https://longbridge.com/en/news/285953639.md)
- [Sangoma Announces Third Quarter Fiscal 2026 Results | SANG Stock News](https://longbridge.com/en/news/286317217.md)
- [Electro-Sensors GAAP EPS of -$0.03, revenue of $2.6M](https://longbridge.com/en/news/286518577.md)
- [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md)